Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b multiple-dose JNJ-53718678 in hospitalized infants with RSV
NL-OMON42680Phase 1Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing JNJ-53718678 with Placebo (2 arms). Primary endpoints: Pharmacokinetic parameters of JNJ-53718678 and Safety and tolerability. Planned start Dec 2015; status: withdrawn.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on NL-OMON42680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42680.